Protein, Nucleic Acid, and Nanomaterial Engineering for Biosensors and Monitoring.

Abstract

The engineering of proteins, nucleic acids, and nanomaterials has significantly advanced the development of biosensors for the monitoring of rare diseases. These innovative biosensing technologies facilitate the early detection and management of conditions that often lack adequate diagnostic solutions. By utilizing engineered proteins and functional nucleic acids, such as aptamers and nucleic acid sensors, these biosensors can achieve high specificity in identifying the biomarkers associated with rare diseases. The incorporation of nanomaterials, like nanoparticles and nanosensors, enhances sensitivity and allows for the real-time monitoring of biochemical changes, which is critical for timely intervention. Moreover, integrating these technologies into wearable devices provides patients and healthcare providers with continuous monitoring capabilities, transforming the landscape of healthcare for rare diseases. The ability to detect low-abundance biomarkers in varied sample types, such as blood or saliva, can lead to breakthroughs in understanding disease pathways and personalizing treatment strategies. As the field continues to evolve, the combination of protein, nucleic acid, and nanomaterial engineering will play a crucial role in developing next-generation biosensors that are not only cost-effective but also easy to use, ultimately improving outcomes and the quality of life for individuals affected by rare diseases.